Compare NEXA & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEXA | ANAB |
|---|---|---|
| Founded | 1956 | 2005 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2017 | 2015 |
| Metric | NEXA | ANAB |
|---|---|---|
| Price | $10.83 | $55.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $7.80 | ★ $66.70 |
| AVG Volume (30 Days) | ★ 716.6K | 442.1K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | $6.99 | N/A |
| Revenue Next Year | N/A | $43.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $4.62 | $15.32 |
| 52 Week High | $14.94 | $63.47 |
| Indicator | NEXA | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 54.46 |
| Support Level | $4.86 | $43.67 |
| Resistance Level | $14.94 | $57.70 |
| Average True Range (ATR) | 0.82 | 3.58 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 3.17 | 25.30 |
Nexa Resources SA is a low-cost integrated zinc producer. It produces copper, silver, and gold as byproducts. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).